Results 31 to 40 of about 7,222 (160)
Side Effects and Efficacy of CoronaVac® Covid-19 Vaccination
, 2023 Side Effects and Efficacy of CoronaVac® Covid-19 Vaccination: Investigation in North Jakarta District Public Health Center Communities in ...
Diana Laila Ramatillah (9907932)
core +1 more source
, 2022 CoronaVac, also known as the Sinovac inactivated SARS-CoV-2 vaccine, has been widely implemented in combating the COVID-19 pandemic. We summarized the results of clinical trials and real-world studies of CoronaVac in this review. The overall efficacy for
Li, Zhuopei +9 more
core +1 more source
Anaphylaxis is rare due to CoronaVac in a population of healthcare workers
Asia Pacific Allergy, 2022 Background CoronaVac, the first coronavirus disease 2019 vaccine administered in our country, was found safe in clinical trials. Objective We aimed to reveal the rate and features of CoronaVac vaccine-associated allergic reactions among vaccinated healthcare workers (HCWs) in real ...
Öztürk, Betül Özdel +5 more
openaire +2 more sources
The efficacy of BNT162b2 (Pfizer–BioNTech) and CoronaVac vaccines in patients with cancer
Journal of Medical Virology, 2022 AbstractAlthough vaccination is efficacious and prevents infection in the general population, there is limited data about Coronavirus disease‐19 (Covid‐19) occurrence after vaccination in cancer patients. It was aimed to evaluate the efficacy of BNT162b2 (Pfizer–BioNTech) and CoronaVac vaccines against Covid‐19 in patients with cancer.
Melih Simsek +6 more
openaire +3 more sources
Heterologous Booster with BNT162b2 Induced High Specific Antibody Levels in CoronaVac Vaccinees
, 2023 Immune responses after COVID-19 vaccination should be evaluated in different populations around the world. This study compared antibody responses induced by ChAdOx1 nCoV-19, CoronaVac, and BNT162b2 vaccines.
Carolina do Prado Servian +10 more
core +1 more source
Vaccine Effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 Omicron BA.2 in CKD [PDF]
, 2023 Background: The ongoing coronavirus disease 2019 (COVID-19) pandemic has posed increased risks of hospitalization and mortality in patients with underlying CKD.
Lai, Francisco Tsz Tsun +11 more
core +1 more source
, 2022 The emergence of SARS-CoV-2 variants raises concerns of reduced COVID-19 vaccine efficacy. We investigated the humoral immunity in uninfected and previously infected ChAdOx1 nCoV-19, BNT162b2 and CoronaVac vaccinees, who have received complete regimes of
Chua, Jia Xin +7 more
core +1 more source
Cellular Immune Response Induced by mRNA Vaccines Against SARS‐CoV‐2
Immunity, Inflammation and Disease, Volume 14, Issue 3, March 2026.SARS‐CoV‐2 vaccine induces cellular immune response. T‐cells play a protective role for COVID‐19. ABSTRACT The disease caused by SARS‐CoV‐2 is known as COVID‐19, and it can range from mild symptoms to severe clinical manifestations, including respiratory failure, pneumonia, and organ failure. Since its emergence in 2019, more than 7 million deaths have
Valentina Tovar +4 more
wiley +1 more source
Boosting immunity after CoronaVac [PDF]
The Lancet, 2022 Sester, Martina, Becker, Sören L
openaire +2 more sources
Journal of Medical Virology, Volume 98, Issue 3, March 2026.ABSTRACT Complement temporal activation kinetics, activation pathways, and their relationship with thromboinflammation and antibody responses in severe vaccination‐COVID‐19 remains unclear. Based on a vaccinated‐infected cohort, we analyzed complement immune responses across mild to critical COVID‐19 cases by a dynamic model.
Jinpeng Cao +16 more
wiley +1 more source